Hypercholesterolemia
Drug research and approvals for hypercholesterolemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 88 studies of hypercholesterolemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 49 drug trials for it since 2013, FDA has 12 approved and 12 open orphan designations naming it, and the EU has 6 authorised medicines for it.
- Recruiting worldwide: 88
- Trials authorized in Canada: 49
- FDA orphan approvals: 12
- EU medicines: 6
Recruiting Now
Newest start dates first, of 88 recruiting on ClinicalTrials.gov ↗- Food Supplement for Individuals With Polygenic HypercholesterolaemiaNCT07918677 · Not applicable · ESI · starts Oct 30, 2026
- A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)NCT07821944 · Phase 3 · Merck Sharp & Dohme LLC · starts Oct 15, 2026
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaNCT07473843 · Phase 3 · Arrowhead Pharmaceuticals · starts Oct 1, 2026
- A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for Cardiovascular DiseaseNCT07839936 · Phase 2 · Verve Therapeutics, Inc. · starts Sep 24, 2026
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients…NCT07619118 · Phase 3 · AstraZeneca · starts Sep 10, 2026
- A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and…NCT07619131 · Phase 3 · AstraZeneca · starts Aug 12, 2026
- A Post-Marketing Clinical Trial of Pemafibrate in Patients with Hypercholesterolemia and Inadequate Response to StatinsNCT07634484 · Phase 4 · Kowa Company, Ltd. · starts Jul 1, 2026
- A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)NCT07428473 · Phase 1 · Monash University · starts Jun 30, 2026
- "Detection and Follow-up of Coronary Lesions in HeFH (DESTINY-FH Study)"NCT07427472 · Not applicable · Assistance Publique - Hôpitaux de Paris · starts Jun 19, 2026
- Comparison of Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin in Chronic Limb-Threatening IschemiaNCT07832578 · Early Phase 1 · King Edward Medical University · starts Jun 1, 2026
Trials Authorized in Canada
The 10 newest of 49; search them all in Canada trials| Aug 7, 2026 | An operationally seamless phase 2/3 study to evaluate the safety, efficacy, and pharmacokinetics of enlicitide decanoate in pediatric participants with…ENLICITIDE (MK-0616) | Merck & Co. (MSD) | Pending |
| Jul 17, 2026 | A phase III randomised, double-blind, factorial design study to assess the effect of fixed dose combination laroprovstat/rosuvastatin compared with…LAROPROVSTAT / ROSUVASTATIN / LAROPROVSTAT-ROSUVASTATIN | AstraZeneca Pharmaceuticals LP | Ongoing |
| Jul 17, 2026 | A phase III randomised, double-blind, parallel-group study to assess the effect of fixed dose combination laroprovstat/rosuvastatin compared with rosuvastatin…ROSUVASTATIN / LAROPROVSTAT-ROSUVASTATIN | AstraZeneca Pharmaceuticals LP | Pending |
| Oct 8, 2025 | Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (yosemite)ZODASIRAN (ARO-ANG3, ADS-004) | ARROWHEAD PHARMACEUTICALS, INC. | Ongoing |
| May 16, 2025 | A phase III, randomised, double-blind, placebo-controlled, parallel-group study to assess the effect of azd0780 on low-density lipoprotein cholesterol in…LAROPROVSTAT (AZD0780) | AstraZeneca Pharmaceuticals LP | Ongoing |
| Jun 5, 2024 | A phase 3, randomized, double-blind study to evaluate the efficacy and safety of mk-0616 compared with ezetimibe or bempedoic acid or ezetimibe and bempedoic…MK-0616 / BEMPEDOIC ACID / EZETIMIBE | Merck & Co. (MSD) | Closed |
| Jun 3, 2024 | A phase 3, open-label extension study to evaluate the safety and efficacy of mk-0616 in adults with hypercholesterolemiaENLICITIDE DECANOATE (MK-0616) | Merck & Co. (MSD) | Ongoing |
| Feb 22, 2024 | Open-label, phase lb, single ascending dose study to evaluate the safety of verve-102 administered to patients with heterozygous familial hypercholesterolemia…VERVE-102 | VERVE THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF ELI LILLY AND COMPANY | Ongoing |
| Jun 28, 2023 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of mk¿0616 in adults with heterozygous familial…ENLICITIDE DECANOATE (MK-0616) | Merck & Co. (MSD) | Closed |
| Feb 10, 2023 | Safety and effectiveness of evinacumab for the treatment of homozygous familial hypercholesterolemia in a real life setting in canadaEVKEEZA (EVINACUMAB (REGN1500)) | ECOGENE-21 | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 24| Feb 12, 2026 | Leqvioas an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in pediatric patients aged 12 years and older with… | Novartis Pharmaceuticals Corporation | Approved |
| Oct 9, 2025 | Praluentas an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in adults with homozygous familial… | Regeneron Pharmaceuticals, Inc. | Approved |
| Sep 25, 2025 | Evkeezaas an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and… | Regeneron Pharmaceuticals, Inc. | Approved |
| Aug 21, 2025 | Repathaas an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults and pediatric patients aged 10 years and… | Amgen Inc. | Approved |
| Mar 21, 2023 | Evkeezaas an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients,… | Regeneron Pharmaceuticals, Inc. | Approved |
| Sep 24, 2021 | RepathaAs an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and… | Amgen Inc. | Approved |
| Apr 1, 2021 | Praluentas an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C | Regeneron Pharmaceuticals, Inc. | Approved |
| Feb 11, 2021 | Evkeezaadjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12… | Regeneron Pharmaceuticals, Inc. | Approved |
| May 27, 2016 | CrestorAn adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial… | iPR Pharmaceuticals, Inc. | Approved |
| Aug 27, 2015 | RepathaAs an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require… | Amgen Inc. | Approved |
| Jan 29, 2013 | KYNAMROAdjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total… | Kastle Therapeutics, LLC | Approved |
| Dec 21, 2012 | JuxtapidAdjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein… | Chiesi Farmaceutici S.p.A. | Approved |
| Sep 11, 2026 | messenger RNA encoding for adenine base editor protein and…treatment of homozygous familial hypercholesterolemia | Verve Therapeutics, a Wholly Owned Subs of Eli Lilly and Co | Designated |
| Aug 14, 2025 | recombinant adeno-associated virus serotype 8 vector…treatment of homozygous familial hypercholesterolemia | NGGT INC. | Designated |
| May 15, 2025 | mRNA encoding the cholesterol degrading platform (CDP)…treatment of homozygous familial hypercholesterolemia (HoFH) | Repair Biotechnologies, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jun 17, 2021 | Evkeezaevinacumab | Ultragenyx Germany GmbH | EMA ↗ |
| Dec 9, 2020 | Leqvioinclisiran | Novartis Europharm Limited | EMA ↗ |
| Apr 1, 2020 | Nilemdobempedoic acid | Daiichi Sankyo Europe GmbH | EMA ↗ |
| Mar 27, 2020 | Nustendibempedoic acid;ezetimibe | Daiichi Sankyo Europe GmbH | EMA ↗ |
| Jul 31, 2013 | Lojuxtalomitapide | Chiesi Farmaceutici SpA | EMA ↗ |
| Mar 9, 2004 | Cholestagelcolesevelam | CHEPLAPHARM Arzneimittel GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA